A Phase I Trial to Evaluate Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Γ Δ T Cells in Subjects with Advanced Solid Tumors or Hematological Malignancies (the ANGELICA Trial)
CANCER RESEARCH（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要